1018 related articles for article (PubMed ID: 28324750)
1. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
Moy JD; Moskovitz JM; Ferris RL
Eur J Cancer; 2017 May; 76():152-166. PubMed ID: 28324750
[TBL] [Abstract][Full Text] [Related]
2. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data.
Swanson MS; Sinha UK
Oral Oncol; 2015 Jan; 51(1):12-5. PubMed ID: 25459157
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in head and neck cancer: evidence and perspectives.
Tosoni A; Franceschi E; Pasquini E; Lanese A; Donini E; Foschini MP; Dall'Olio D; Brandes AA
Immunotherapy; 2017 Dec; 9(16):1351-1358. PubMed ID: 29185392
[TBL] [Abstract][Full Text] [Related]
4. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer.
Hashemi-Sadraei N; Sikora AG; Brizel DM
Am Soc Clin Oncol Educ Book; 2016; 35():e277-82. PubMed ID: 27249733
[TBL] [Abstract][Full Text] [Related]
6. Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.
Haque S; Yellu M; Randhawa J; Hashemi-Sadraei N
Drug Des Devel Ther; 2017; 11():2537-2549. PubMed ID: 28919706
[TBL] [Abstract][Full Text] [Related]
7. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Saâda-Bouzid E; Defaucheux C; Karabajakian A; Coloma VP; Servois V; Paoletti X; Even C; Fayette J; Guigay J; Loirat D; Peyrade F; Alt M; Gal J; Le Tourneau C
Ann Oncol; 2017 Jul; 28(7):1605-1611. PubMed ID: 28419181
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint immunotherapy in head and neck cancers.
Zolkind P; Uppaluri R
Cancer Metastasis Rev; 2017 Sep; 36(3):475-489. PubMed ID: 28836124
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
Przybylski K; Majchrzak E; Weselik L; Golusiński W
Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
[TBL] [Abstract][Full Text] [Related]
11. Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.
Bauman JE; Ferris RL
Cancer; 2014 Mar; 120(5):624-32. PubMed ID: 24222079
[TBL] [Abstract][Full Text] [Related]
12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
13. [Immunocheckpoint inhibition in head and neck squamous cell carcinoma: the current status and progress].
Huang LL; Shi YK
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):641-647. PubMed ID: 31550852
[TBL] [Abstract][Full Text] [Related]
14. The benefits of immunotherapy combinations.
Schmidt C
Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
[No Abstract] [Full Text] [Related]
15. [Not Available].
Reverdy T; Gau M; Karabajakian A; Neidhardt EM; Fayette J
Bull Cancer; 2018 Dec; 105 Suppl 1():S35-S42. PubMed ID: 30595197
[TBL] [Abstract][Full Text] [Related]
16. Advances in the Immunobiological Therapies for Advanced Melanoma.
Pérez Gago MC; Saavedra Santa Gadea O; de la Cruz-Merino L
Actas Dermosifiliogr; 2017 Oct; 108(8):721-728. PubMed ID: 28388991
[TBL] [Abstract][Full Text] [Related]
17. [Immunomodulation as innovative therapy for head and neck tumors : Current developments].
Schuler PJ; Doescher JC; Laban S; Hoffmann TK
HNO; 2016 Jul; 64(7):470-8. PubMed ID: 26912050
[TBL] [Abstract][Full Text] [Related]
18. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
Spain L; Larkin J
Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
[No Abstract] [Full Text] [Related]
19. Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.
Economopoulou P; Kotsantis I; Psyrri A
Curr Treat Options Oncol; 2016 Aug; 17(8):40. PubMed ID: 27315066
[TBL] [Abstract][Full Text] [Related]
20. A decade of immune-checkpoint inhibitors in cancer therapy.
Robert C
Nat Commun; 2020 Jul; 11(1):3801. PubMed ID: 32732879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
